ABSTRACT
Bcl-2 expression was evaluated in a series of twenty cytologically positive prostatic carcinoma and was correlated with the cytologic grade of the tumor. In aspirated cells, the intensity of immunostaining was more frequent in high grade tumors [5 cases, 25%] than in intermediate grade [6 cases, 30%] or low grade tumors [9 cases, 45%]. There was a significant correlation [p = 0.027] between Bcl-2 expression and cytologic tumor grade. One patient was misdiagnosed as benign prostatic hyperplasia on histopathology but the diagnosis was proven to be well differentiated low grade prostatic carcinoma on application of Bcl-2 immunostaining. Bcl-2 immunostaining of specimens taken by FNAs of prostatic carcinoma is a potential tool to confirm or correct conflicting diagnosis. Bcl-2 is beneficial for diagnosis and grading of prostatic carcinoma. In addition, Bcl-2 can be used as a diagnostic marker of hormone refractory prostatic carcinoma and can be a very beneficial prognostic factor in metastatic prostate carcinoma